Esperion Reiterates Its Full Year 2024 Operating Expense Guidance Of Approximately $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics has reiterated its full-year 2024 operating expense guidance of approximately $225M-$245M, which includes $20M in non-cash expenses related to stock compensation.
August 12, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Esperion Therapeutics has reiterated its full-year 2024 operating expense guidance of approximately $225M-$245M, including $20M in non-cash expenses related to stock compensation.
Reiterating the operating expense guidance provides clarity and stability for investors, but it does not introduce new information that would significantly impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100